

Published in final edited form as:

Eur J Med Chem. 2011 September ; 46(9): 4178–4183. doi:10.1016/j.ejmech.2011.06.020.

Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents

Qiang Wang^a, Weidong Hu^a, Shuyang Wang^a, Zhenliang Pan^a, Le Tao^b, Xiaohe Guo^b, Keduo Qian^c, Chin-Ho Chen^d, Kuo-Hsiung Lee^{c,e,*}, and Junbiao Chang^{a,*}

^aDepartment of Chemistry, Zhengzhou University, Zhengzhou 450001, PR China

^bHena Key Laboratory of Fine Chemical, Zhengzhou 450002, PR China

^cNatural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA

^dDepartment of Surgery, Duke University Medical Center, Durham, NC 27710, USA

^eChinese Medicine Research and Development Center, China Medical University and Hospital, Taichung, Taiwan

Abstract

We prepared 1-(4'-azido-2'-deoxy-2'-fluoro- β -D-arabinofuranosyl)cytosine (**10**) and its hydrochloride salt (**11**) as potential antiviral agents based on the favorable antiviral profiles of 4'-substituted nucleosides. Compounds **10** and **11** were synthesized from 1,3,5-*O*-tribenzoyl-2-deoxy-2-fluoro-D-arabinofuranoside in multiple steps, and their structures were unequivocally established by IR, ¹H NMR, ¹³C NMR, and ¹⁹F NMR spectroscopy, HRMS, and X-ray crystallography. Compounds **10** and **11** exhibited potent anti-HIV-1 activity (EC₅₀: 0.3 and 0.13 nM, respectively) without significant cytotoxicity in concentrations up to 100 μ M. Compound **11** exhibited extremely potent anti-HIV activity against NL4-3 (wild-type), NL4-3 (K101E), and RTMDR viral strains, with EC₅₀ values of 0.086, 0.15, and 0.11 nM, respectively. Due to the high potency of **11**, it was also screened against an NIH Reagent Program NRTI-resistant virus panel containing eleven mutated viral strains and for cytotoxicity against six different human cell lines. The results of this screening indicated that **11** is a novel NRTI that could be developed as an anti-AIDS clinical trial candidate to overcome drug-resistance issues.

Keywords

4'-Azido-2'-deoxy-2'-fluoro nucleosides; Anti-HIV activity; Nucleoside reverse transcriptase inhibitor (NRTI); Drug resistance

© 2011 Elsevier Masson SAS. All rights reserved.

*Corresponding authors. For K.H.L. Tel.: (919) 962-0066; fax: (919) 966-3893 (K.H. Lee). Tel.: +86-371-67783017; fax: +86-371-67783017 (J. Chang), khlee@unc.edu (K.H. Lee), changjunbiao@zzu.edu.cn (J. Chang).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1. Introduction

Since the discovery of the human immunodeficiency virus (HIV) in 1983, AIDS has become the leading infectious cause of death worldwide. According to the World Health Organization (07 AIDS Epidemic Update), there were 33.2 million people living with AIDS worldwide in 2007, 2.1 million deaths from AIDS, and 2.5 million newly infected patients with AIDS. Over the last two decades, tremendous effort has been directed to the discovery and development of novel agents for the treatment of HIV infections and great successes have been achieved. So far, there are more than 20 approved anti-HIV drugs, belonging to seven classes [1].

Nucleoside reverse transcriptase inhibitors (NRTIs) are one of the most important classes of compounds active against HIV replication and have been used extensively to treat HIV infection [2]. However, the long term use of antiviral nucleoside analogs is inevitably associated with delayed toxicity and/or development of drug-resistant virus [3–6], which limits their effectiveness as an AIDS treatment. Therefore, there remains a need for the development of novel anti-HIV agents with better therapeutic indices, new mechanisms of action, and activity against HIV strains resistant to currently available drugs.

All clinical NRTIs belong to the family of 2',3'-dideoxynucleoside (ddN) [7]. As the chain terminator of proviral DNA biosynthesis, the ddN structure has been assumed to be essential for an active nucleoside derivative. However, resistant HIV variants and other side effects have emerged. Resistance to these ddNs results from HIV mutants that have acquired the ability to discriminate between ddN and physiologic 2'-deoxynucleoside (dN), do not accept ddN into the active center of their reverse transcriptase (RT), and selectively cut off the incorporated ddN from their proviral DNA terminus. Therefore, nucleoside drugs that could prevent the emergence of drug-resistant HIV variants must have a 3'-OH as the chain terminator of proviral DNA biosynthesis.

A 4'-C-substituted-2'-deoxynucleoside (4'sdN) satisfies these conditions, because 4'sdN has all of the functional groups of dN, making it difficult for HIV to discriminate between a 4'sdN and dN. At the same time, the 3'-OH group of 4'sdN would not be useful for elongation of proviral DNA biosynthesis. Thus, 4'sdN could be the chain-terminator of proviral DNA biosynthesis and active against HIV as well as HIV strains resistant to current ddN drugs. In addition, modification of the carbohydrate moiety of nucleosides with electron-withdrawing groups can greatly affect the nucleoside's electronic properties and conformational shape [8–14], which often leads to dramatically improved activities. Therefore, we incorporated a fluorine atom, which has the strongest electron-withdrawing property of the halogens atoms, into our newly designed 4'sdN. Moreover, azido, cyano, and ethynyl groups, which have characteristic electronic and structural features due to their *sp* hybridization, are present in many biologically active compounds [15–17]. It has been proposed that the furanose ring of 4'-C-azidothymidine exhibits an unnatural 3'-*C-endo* conformation, and the compound was active against multidrug-resistant strains of HIV (EC₅₀: 0.34 μM) [18]. Therefore, we were interested in designing novel 4'sdN compounds with such substitutions at the 4'-position. Herein, we report the synthesis and evaluation of 1-(4'-azido-2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)cytosine (**10**) (Fig. 1) as a novel potent NRTI that could overcome drug-resistance problems [19–21].

2. Chemistry

The synthesis of **10** is illustrated in Scheme 1. According to the reported method [8, 13, 19–25], treatment of commercially available 1,3,5-*O*-tribenzoyl-2-deoxy-2-fluoro-D-arabinofuranoside (**1**) with HBr-HOAc (45%) in dichloromethane (DCM) gave exclusively the α-bromide **2**, which was coupled with silylated uracil in chloroform to provide the β-

nucleoside analog **3** in a good yield after recrystallization. Deprotection of **3** with methanolic ammonia afforded nucleoside **4** in excellent yield. The 4'-azido substitution was introduced using the following procedure modified from the previously reported method [26]. Treatment of **4** with I₂/Ph₃P in tetrahydrofuran (THF) followed by elimination in the presence of sodium methoxide (NaOMe) gave 4'-methylene-nucleoside **6**. Treatment of **6** with ICl/NaN₃ in THF afforded 4'-azido-nucleoside **7**. Benzoylation of **7** followed by treatment with *m*-chloroperbenzoic acid (*m*-CPBA) in the presence of *m*-chlorobenzoic acid (*m*-CBA) yielded a protected 4'-azido-uridine analog **9**. Treatment of **9** with triazole/POCl₃ followed by methanolic ammonia gave our target **10**. Compound **10** was dissolved in methanol and treated with a solution of hydrogen chloride in ethyl acetate. The product separated as a solid and was collected by filtration to afford the hydrochloride salt (**11**) of **10**. The solid-state structure of **11** was determined by single-crystal X-ray crystallography (Fig. 2). Crystallographic data (excluding structure factors) for the structures in this paper have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication (nos. CCDC 740473). Copies of the data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK, (fax: +44-(0)1223-336033 or e-mail: deposit@ccdc.cam.ac.uk).

3. Results and discussion

The anti-HIV activity of **10** and **11** was first evaluated in vitro according to standard procedures using efavirenz (EFV) and zidovudine (AZT) as controls (Table 1) [27–31]. Compounds **10** and **11** exhibited extremely potent antiviral activity with EC₅₀ values of 0.3 and 0.13 nM, respectively, compared with EFV (EC₅₀: 1.2 nM) and AZT (EC₅₀: 47 nM). The increased activity of **11** compared with **10** likely reflects its increased solubility of **11** in water [32]. Both compounds did not show significant cytotoxicity in concentrations up to 100 μM against the MT-2 cell line using the MTT assay. In the further evaluation of **11**, we discovered that it retained its sub-nanomolar activity against drug-resistant HIV strains NL4-3 (K101E) and RTMDR (Table 2). K101E tends to decrease viral susceptibility to all nucleoside RT inhibitors, while RTMDR is a multiple RT inhibitor-resistant strain, which is insensitive to AZT, ddI, nevirapine, and other NNRTIs. In our screening, **11** exhibited extremely potent anti-HIV activity against NL4-3 (wild-type), NL4-3 (K101E), and RTMDR, with EC₅₀ values of 0.086, 0.15, and 0.11 nM, respectively. These findings suggested that **11** has a great potential to be developed as a novel NRTI.

Therefore, in the following study, we further evaluated the anti-HIV potential of **11** using a panel of eleven NRTI resistant viral strains from the NIH Reagent Program. As shown in Table 3, **11** retained its nanomolar activity against resistant strains 7324-1, 7324-4, 7303-3, 35764-2, and 56252-1 with EC₅₀ values of 0.595, 0.735, 0.56, 0.42, 0.525 nM, respectively, which were similar to that of **11** against the wild type NL4-3 (EC₅₀: 0.318 nM). However, **11** partially or completely lost its nanomolar inhibitory activity against 10076-4, 7295-1, 4755-5, 6463-13, 1617-1, and 29129-2. After carefully analyzing the mutations of these resistant viral strains, we discovered that one single mutation M184V may lead to the substantially reduced antiviral activity of **11**. This M184V mutation in RT was discovered previously to be 3TC treatment-associated, and it was also found that the M184V mutation increases the HIV sensitivity to AZT in AZT-resistant viruses, suggesting that compound **11** may be used in combination with AZT to reduce the influence of resistance issues.

The cytotoxicity profiles of **11** were further evaluated using six human cell lines different from the previously used MT-2 cell line (Table 4). A Promega CellTiter-Glo Luminescent Cell Viability Assay was used to determine the number of viable cells based on quantitation of the presence of ATP, which signals the presence of metabolically active cells. Compound **11** showed little cytotoxicity against TZM-BL, HEPG-2, and 293T cells with IC₅₀ values

over 140 μM , resulting in therapeutic index (TI) values of $>280,000$. Comparatively, **11** showed some cytotoxicity against MT4, ACH-2, and PBMC cells with IC_{50} values of 0.12, 0.11, and 0.15 μM , and corresponding TI values of 1418, 1255, and 1709. Overall, **11** showed less toxicity to adherent cells compared to suspension cells. Nevertheless, the TI values were still greater than at least one thousand.

Regarding mechanism of action, compound **10** is likely to have a strong binding in the active site of HIV RT due to the introduction of fluorine at the 2'-position. Although compound **10** possesses a 3'-hydroxy group, it might act like a DNA chain terminator similar to 4'-azido thymidine (Fig. 3). Based on the drug profile shown in Table 3 against resistant virus strains, D67 and M184 are likely the two critical amino acid residues in the NRTI binding site of HIV-1 RT that interact intimately with the compound. NRTI resistant viruses with D67N or M184V mutation are markedly resistant to compound **10**. Thus, the compound is likely to bind between the palm and the finger subdomains of HIV-1 RT and make critical interactions with residues including D67 and M184.

4. Conclusion

In summary, novel 4'sdN compounds **10** and **11** were designed, synthesized, and evaluated for anti-HIV activity. The hydrochloride salt **11** retained its sub-nanomolar activity against NRTI-resistant (K101E) and multi-drug-resistant HIV strains (RTMDR). In further studies, **11** also showed nanomolar activity against resistant viral strains, except for the M184V single mutation. Compound **11** showed little cytotoxicity against adherent cells and marginal cytotoxicity against suspension cells with TI values over one thousand. Overall, compound **11** merits further development as an anti-AIDS clinical trial candidate.

5. Experimental

All chemical reagents were commercially available and column chromatography was performed on silica gel 200–300 mesh (Yantai Silica Gel Co. LTD). Analytical TLC was performed on silica gel GF₂₅₄. Melting points were recorded with an XT-4 melting point apparatus and are uncorrected. IR spectra were obtained on a NICOLET 6700 spectrometer. ¹H, ¹⁹F, and ¹³C NMR spectra were obtained with a Bruker AV-300 spectrometer. Chemical shifts are reported as δ (ppm) downfield with respect to an internal standard of tetramethylsilane (TMS). High-resolution mass spectra (HRMS-ESI) were obtained on a MicroTM Q-TOF Mass Spectrometer. Elemental analyses were performed with a Carlo-Erba 1106 C, H, and N analyzer. LC-MS spectra were measured on an Agilent MSD-1100 ESI-MS/MS system. X-ray crystallography was obtained on Rigaku Saturn 724 CCD diffractometer.

5.1. Synthesis of 1-(2-deoxy-2-fluoro-3,5-di-O-benzoyl- β -D-arabino-furanosyl)uracil (**3**)

To a solution of 1,3,5-*O*-tribenzoyl-2-deoxy-2-fluoro-D-arabinofuranoside (**1**) (20.0 g, 43.1 mmol) in anhydrous DCM (400 mL) was added HBr-HOAc (45% v/v, 50 mL, 271 mmol) dropwise under nitrogen at 0 C and the resulting solution was stirred at room temperature for 20 h. The solution was washed with saturated NaHCO₃ (3 \times 100 mL), dried over Na₂SO₄, filtered, and concentrated to give compound **2** as syrup, which was used in the next step without further purification.

A mixture of uracil (12.6 g, 113.0 mmol) and (NH₄)₂SO₄ (1.57 g) in hexamethyldisilazane (HMDS) (1.5 L) was refluxed under nitrogen for 20 h, and the homogeneous solution obtained was evaporated to dryness under vacuum to give the silylated uracil. To the silylated uracil residue was added a solution of compound **2** in CHCl₃ (800 mL) and the mixture was refluxed under nitrogen for 24 h. The reaction was quenched by addition of ice-

water and filtered. The aqueous layer was extracted with DCM (3×200 mL) and the combined organic solution was washed with brine, dried over Na₂SO₄, filtered, and concentrated to give a white solid, which was recrystallized with 5% EtOH-DCM to give compound **3** (16.7 g, 84.2%). ¹H NMR (300 MHz, CDCl₃) δ 8.35 (1H, brs, NH), 7.43-8.11 (11H, m, Ar-H, H-6), 6.33 (1H, dd, *J* = 21.59, 2.93 Hz, H-1'), 5.69 (1H, d, *J* = 8.05 Hz, H-5), 5.63 (1H, dd, *J* = 17.20, 2.93 Hz, H-3'), 5.34 (1H, dd, *J* = 50.13, 2.93 Hz, H-2'), 4.78 (2H, d, *J* = 4.39 Hz, H-5'), 4.52 (1H, m, H-4'); ESI- MS: *m/z* 455 [M+H]⁺; Anal. calcd (C₂₃H₁₉FN₂O₇): C, 60.79; H, 4.21; N, 6.16; found: C, 60.75; H, 4.24; N, 6.11.

5.2. Synthesis of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)uracil (4)

A solution of compound **3** (7.79 g, 17.1 mmol) in saturated NH₃-MeOH (200 mL) was stirred at room temperature for 24 h and evaporated to dryness under reduced pressure. DCM (25 mL) was added to the residue and the mixture was stirred at room temperature for 1 h. The white solid was collected by filtration to give compound **4** (3.93 g, 93.0%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.35 (1H, brs, NH), 7.71 (1H, dd, *J* = 8.05, 1.46 Hz, H-6), 6.10 (1H, dd, *J* = 16.10, 4.39 Hz, H-1'), 5.87 (1H, d, *J* = 5.12 Hz, 3'-OH), 5.64 (1H, d, *J* = 8.05 Hz, H-5), 5.08 (1H, t, *J* = 5.85 Hz, 5'-OH), 5.03 (1H, ddd, *J* = 52.69, 4.03, 2.93 Hz, H-2'), 4.21 (1H, dm, *J* = 19.76 Hz, H-3'), 3.79 (1H, m, H-4'), 3.60 (2H, m, H-5'); ESI-MS: *m/z* 269 [M+Na]⁺; Anal. calcd (C₉H₁₁FN₂O₅): C, 43.91; H, 4.50; N, 11.38; found : C, 43.90; H, 4.29; N, 11.33.

5.3. Synthesis of 1-(2,5-dideoxy-2-fluoro-5-iodo-β-D-arabino-furanosyl)uracil (5)

To a solution of compound **4** (3.73 g, 15.2 mmol), imidazole (2.06 g, 30.3 mmol), and triphenylphosphine (5.96 g, 22.7 mmol) in THF (100 mL) was added a solution of iodine (5.77 g, 22.7 mmol) in THF (50 mL) dropwise at 0 °C. The reaction mixture was stirred at room temperature overnight and quenched with a saturated solution of Na₂SO₃, extracted with EtOAc (2×100 mL). The combined organic solution was washed with water, brine, dried over Na₂SO₄, filtered, and concentrated to yield a thick oil, which was purified by silica gel column chromatography (1–5% MeOH in DCM) to afford compound **5** (4.51 g, 83.5%). ¹H NMR (300 MHz, DMSO-*d*₆) δ 11.50 (1H, br s, NH), 7.58 (1H, dd, *J* = 8.14, 1.95 Hz, H-6), 6.17 (1H, dd, *J* = 18.40, 3.99 Hz, H-1'), 6.15 (1H, br, 3'-OH), 5.67 (1H, d, *J* = 8.14 Hz, H-5), 5.08 (1H, ddd, *J* = 52.41, 3.84, 2.55 Hz, H-2'), 4.14 (1H, ddd, *J* = 19.68, 4.21, 2.65 Hz, H-3'), 3.87 (1H, dd, *J* = 11.02, 5.19 Hz, H-4'), 3.43-3.57 (m, 2H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ 6.2, 76.7, 82.0, 83.0, 95.3, 101.4, 141.2, 150.0, 162.8; ESI-MS: *m/z* 379 [M+23]⁺; Anal. calcd (C₉H₁₀FIN₂O₄): C, 30.36; H, 2.83; N, 7.87; found: C, 30.30; H, 2.88; N, 7.84.

5.4. Synthesis of 1-(2,5-dideoxy-2-fluoro-β-D-arabino-4-eno-furanosyl)uracil (6)

A solution of compound **5** (4.2 g, 11.8 mmol) in dry MeOH (40 mL) containing MeONa (25% wt in MeOH, 10.2 mL, 47.3 mmol) was heated to 65 °C for 3 h and an additional aliquot of MeONa (25% wt in MeOH, 3.4 mL) was added. After 30 min, the reaction mixture was allowed to stay at room temperature overnight and brine was added. The mixture was adjusted to pH 3 by addition of 1N HCl and the mixture was extracted with EtOAc (2×300 mL). The combined organic solution was dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel column chromatography (2–5% MeOH in DCM) to afford compound **6** (1.94 g, 72.1%). ¹H NMR (300 MHz, CDCl₃) δ 9.05 (1H, br s, NH), 7.32 (1H, dd, *J* = 8.16, 2.31 Hz, H-6), 6.62 (1H, dd, *J* = 20.97, 2.79 Hz, H-1'), 5.76 (1H, d, *J* = 8.22 Hz, H-5), 5.09 (1H, dd, *J* = 51.44, 2.95 Hz, H-2'), 4.76 (1H, d, *J* = 2.74 Hz, =CH₂), 4.73 (1H, d, *J* = 11.46 Hz, H-3'), 4.52 (1H, d, *J* = 2.74 Hz, =CH₂); ESI-MS: *m/z* 227 [M-H]⁺; Anal. calcd (C₉H₉FN₂O₄): C, 47.37; H, 3.98; N, 12.28; found : C, 47.43; H, 3.86; N, 12.13.

5.5. Synthesis of 1-(4-azido-2,5-dideoxy-2-fluoro-5-iodo-β-D-arabino-furanosyl)uracil (7)

To a suspension of NaN_3 (1.38 g, 21.3 mmol) in THF (50 mL) at 0 °C was added ICl (2.31 g, 14.2 mmol). After 10 minutes, a solution of compound **6** (1.62 g, 7.10 mmol) in THF (16 mL) was added dropwise to the mixture and the reaction mixture was stirred at room temperature overnight. Aqueous Na_2SO_3 solution was added and the mixture extracted with EtOAc (3×250 mL). The combined organic solution was dried over Na_2SO_4 , filtered, and concentrated. The residue was purified by silica gel column chromatography (1–5% MeOH in DCM) to afford compound **7** (1.82 g, 64.6%). IR (KBr): 2119 cm^{-1} (N_3); ^1H NMR (300 MHz, MeOH- d_4) δ 7.68 (1H, dd, $J = 8.1, 1.87$ Hz, H-6), 6.46 (1H, dd, $J = 16.07, 4.39$ Hz, H-1'), 5.74 (1H, d, $J = 8.12$ Hz, H-5), 5.22 (1H, ddd, $J = 52.93, 4.36, 3.30$ Hz, H-2'), 4.65 (1H, dd, $J = 18.67, 3.31$ Hz, H-3'), 3.69 (2H, m, H-5'); ESI-MS: m/z 420 [$\text{M}+23$] $^+$; Anal. calcd ($\text{C}_9\text{H}_9\text{FIN}_5\text{O}_4$): C, 27.22; H, 2.28; N, 17.64; found : C, 27.09; H, 2.23; N, 17.73.

5.6. Synthesis of 1-(4-azido-2,5-dideoxy-2-fluoro-3-O-benzoyl-5-iodo-β-D-arabinofuranosyl)uracil (8)

To a solution of compound **7** (1.17 g, 2.95 mmol) in DCM (130 mL) were added Et_3N (0.82 mL, 5.90 mmol) and a catalytic amount of 4-dimethylaminopyridine. The reaction mixture was cooled to 0 °C and benzyl chloride (0.41 mL, 3.54 mmol) was added. After 20 min, water and 2M K_2CO_3 were added, and the mixture was extracted with EtOAc (400 mL). The organic layer was washed with brine (2×50 mL), dried over Na_2SO_4 , filtered, and concentrated. The residue was purified by silica gel column chromatography (0.1–1% MeOH in DCM) to afford compound **8** (1.2 g, 81.2%). IR (KBr): 2118 cm^{-1} (N_3); ^1H NMR (300 MHz, DMSO- d_6) δ 11.63 (1H, br s, NH), 7.57–8.09 (6H, m, Ar-H and H-6), 6.52 (1H, dd, $J = 18.69, 5.52$ Hz, H-1'), 6.07 (1H, dd, $J = 21.57, 4.05$ Hz, H-3'), 5.82 (1H, ddd, $J = 52.21, 5.32, 4.38$ Hz, H-2'), 5.78 (1H, d, $J = 8.14$ Hz, H-5), 3.99 (2H, q, $J = 11.66$ Hz, H-5'); ESI-MS: m/z 524 [$\text{M}+23$] $^+$; Anal. calcd ($\text{C}_{16}\text{H}_{13}\text{FIN}_5\text{O}_5$): C, 38.34; H, 2.61; N, 13.97; found : C, 38.26; H, 2.48; N, 13.85.

5.7. Synthesis of 1-(4-azido-2-deoxy-2-fluoro-3-O-benzoyl-5-O-(3-chlorobenzoyl)-β-D-arabinofuranosyl)uracil (9)

To a solution of **8** (1.10 g, 2.19 mmol) in DCM (100 mL) and water (60 mL) were added successively K_2HPO_4 (0.76 g, 4.38 mmol), $n\text{-Bu}_4\text{NHSO}_4$ (0.82 g, 2.41 mmol), and $m\text{-CBA}$ (0.38 g, 2.41 mmol). The reaction mixture was cooled to 0 °C and $m\text{-CPBA}$ (77%, 1.47 g, 6.57 mmol) was added. The reaction mixture was stirred at room temperature overnight. Na_2SO_3 was added and the mixture was extracted with EtOAc (500 mL). The combined organic solution was washed with Na_2SO_3 (5%), brine, dried over Na_2SO_4 , filtered, and concentrated. The residue was purified by silica gel column chromatography (0.1–0.5% MeOH in DCM) to provide compound **9** (667 mg, 57.5%). IR (KBr): 2117 cm^{-1} (N_3); ^1H NMR (300 MHz, CDCl_3) δ 7.41–8.10 (10H, m, Ar-H and H-6), 6.63 (1H, dd, $J = 18.36, 3.61$ Hz, H-1'), 5.73–5.84 (2H, m, H-3' and H-5), 5.45 (1H, ddd, $J = 51.37, 3.55, 2.03$ Hz, H-2'), 4.86 (2H, q, $J = 11.87$ Hz, H-5'); ESI-MS: m/z 553 [$\text{M}+23$] $^+$; Anal. calcd ($\text{C}_{23}\text{H}_{17}\text{FCIN}_5\text{O}_7$): C, 52.14; H, 3.23; N, 13.22; found : C, 52.03; H, 3.22; N, 13.00.

5.8. Synthesis of 1-(4-azido-2-deoxy-2-fluoro)-β-D-arabinofuranosyl)cytosine (10)

To a solution of compound **9** (0.40 g, 0.75 mmol) in DCM (15 mL) was added 1,2,4-triazole (0.57 g, 8.25 mmol) followed by pyridine (0.67 mL, 8.25 mmol). The solution was cooled to 0 °C and POCl_3 (0.39 mL, 3.75 mmol) was added. The solution was stirred at 0 °C for 2 h then room temperature overnight. The reaction was quenched with water and the mixture was extracted with DCM (2×250 mL). The combined organic solution was dried over Na_2SO_4 , filtered, and concentrated. The residue was dissolved in THF (40 mL) and NH_4OH (33%, 40 mL) was added. The reaction mixture was stirred at room temperature for 1 h.

Solvent was removed and the residue was dissolved in MeOH (40 mL) and 7N NH₃ in MeOH (40 mL) was added. The solution was stirred at room temperature overnight. The solution was concentrated to dryness under reduced pressure and the residue was purified by silica gel column chromatography (1–5% MeOH in DCM) to give compound **10** (92 mg, 41.1%) as a white solid. mp: 86–87 °C; IR (KBr): 2118 cm⁻¹ (N₃); ¹H NMR (300 MHz, MeOH-*d*₄) δ 7.80 (1H, d, *J* = 7.57 Hz, H-6), 6.50 (1H, dd, *J* = 12.10, 4.67 Hz, H-1'), 5.97 (1H, d, *J* = 7.57 Hz, H-5), 5.21 (1H, dt, *J* = 53.52, 4.48 Hz, H-2'), 4.49 (1H, dd, *J* = 21.63, 4.34 Hz, H-3'), 3.84 (2H, s, H-5'); ¹³C NMR (75.47 MHz, MeOH-*d*₄) δ 63.4, 76.5 (*J* = 25.2 Hz), 84.8 (*J* = 17.2 Hz), 96.1, 96.2 (*J* = 193.4 Hz), 98.6 (*J* = 7.5 Hz), 143.0, 157.9, 167.8; ¹⁹F NMR (282.4 MHz, MeOH-*d*₄): -202.5; ESI-TOF/MS for C₉H₁₁FN₆O₄: calcd 287.0904 [M+H]⁺; found: 287.0905[M+H]⁺; Anal. calcd (C₉H₁₁FN₆O₄): C, 37.77; H, 3.87; N, 29.36; found: C, 37.53; H, 3.90; N, 29.19.

5.9. Synthesis of 1-(4-azido-2-deoxy-2-fluoro)-β-D-arabinofuranosyl)cytosine hydrochloride salt (**11**)

Compound **10** (50 mg, 0.17 mmol) was dissolved in MeOH (1 mL) and treated with a solution of hydrogen chloride (20 mmol) in EtOAc (10 mL). The product separated as a solid and was collected by filtration to afford the hydrochloride salt of compound **10** (34 mg, 61.1%). IR (KBr): 2117 cm⁻¹ (N₃); ¹H-NMR (D₂O) δ 7.94 (1H, dd, *J* = 8.05, 1.10 Hz, H-6), 6.54 (1H, dd, *J* = 10.98, 5.12 Hz, H-1'), 6.26 (1H, d, *J* = 8.05 Hz, H-5), 5.39 (1H, dt, *J* = 52.69, 5.12 Hz, H-2'), 4.58 (1H, dd, *J* = 21.59, 4.76 Hz, H-3'), 3.97 (2H, q, *J* = 12.66 Hz, H-5'); ESI-MS: *m/z* 287 [M+H]⁺.

5.10. Single-crystal X-ray diffraction analysis of hydrochloride salt **11**

C₉H₁₁FN₆O₄·HCl, fw = 322.70, Monoclinic P2(1), *a* = 6.5738(13) Å, *b* = 14.309(3) Å, *c* = 7.3271(15) Å, α = γ = 90°, β = 99.68(3)°, *V* = 679.4(2) Å³, *Z* = 2, ρ_{calcd} = 1.577 Mg/m³, λ(Mo-*K*_α) = 0.71073 Å, μ = 0.320 mm⁻¹, *F*(000) = 332, *T* = 293(2). A colorless 0.22 × 0.18 × 0.14 mm³ crystal was used for data collection. The theta range for data collection was 3.14 to 26.01° with 2633 reflections collected.

5.11. Anti-HIV (wt) activity assay

Vesicular stomatitis virus glycoprotein (VSV-G) plasmid was co-transfected with env-deficient HIV vector, pNL4-3.luc.R⁻E⁻ [24, 25], into 293 cells by using modified Ca₃(PO₄)₂ method.²⁶ Briefly, 293 cells (100 mm plate) were transfected with 8 μg HIV vector alone or with 3 μg VSVG DNA. After 16 h, plates were washed with phosphate-buffered saline, and fresh medium was added into the plates. After post-infection for 48 h, the supernatant was harvested and filtered through a 0.45 μm filter. The supernatant contains VSVG/HIV pseudotyped virions and can be used directly or stored at -80 °C.

One hour prior to infection, MT-2 cells were plated on 24-well plates at the density of 1.2 × 10⁵ cells per well. Compound was incubated with target cells for 15 minutes prior to adding VSVG/HIV-1 (0.5 mL/well) for infection. The same amount of solvent alone was used as control. After post-infection for 48 h, cells were spin down and supernatant was discarded. Cells were lysed in 50 μl Cell Lysis Reagent (Promega). Luciferase activity of the cell lysate was measured by a FB15 luminometer (Berthold Detection System) according to the manufacturer's instructions. Compounds **10** and **11** showed dose-dependent inhibition activity on HIV-1 replication with EC₅₀ values of 0.3 nM and 0.13 nM, respectively, and thus, were more potent than AZT (EC₅₀: 47 nM).

5.12. Cell viability assay

Compounds **10** and **11** were evaluated for cell viability by MTT methods [27]. MTT assay was performed in MT-2 cell line. Both compounds had no significant effect on cell growth or any cytotoxic effect on MT-2 cells at a final concentration of 100 μ M.

5.13. Anti-HIV replication assay against NL4-3 (K101E) and RTMDR strains in TZM-bl cell lines

A previously described HIV-1 infectivity assay was used in the experiments [28]. A 96-well cell culture plate was used to set up the virus replication screening assay. NL4-3 (K101E) or RTMDR at a multiplicity of infection (MOI) of 0.001 was used to infect TZM-bl cells. Culture supernatants were collected on day 4 post-infection for a p24 assay using an ELISA kit from PerkinElmer.

Acknowledgments

J. Chang thanks the National Natural Science Foundation of China (#20672030; #30825043) for financial support. Thanks are also due to a grant AI-33066 from the National Institute of Allergy and Infectious Diseases (NIAID) awarded to K.H. Lee.

Abbreviations

IR	infrared
NMR	nuclear magnetic resonance
HRMS	high resolution mass spectrometry
RT	reverse transcriptase
RTMDR	reverse transcriptase multi-drug resistant
NRTI	nucleoside reverse transcriptase inhibitor
NNRTI	non-nucleoside reverse transcriptase inhibitor
HIV	human immunodeficiency virus
AIDS	acquired immunodeficiency syndrome
dN	2'-deoxynucleoside
ddN	2',3'-dideoxynucleoside
4'sdN	4'-C-substituted-2'-deoxynucleoside
DCM	dichloromethane
THF	tetrahydrofuran
<i>m</i>-CPBA	<i>m</i> -chloroperbenzoic acid
<i>m</i>-CBA	<i>m</i> -chlorobenzoic acid
EFV	efavirenz
AZT	zidovudine
HMDS	hexamethyldisilazane
VSV-G	vesicular stomatitis virus glycoprotein

References

1. De Clercq E. Nat Rev Drug Discov. 2007; 6:1001–1018. [PubMed: 18049474]

2. Sharma PL, Nurpeisov V, Hernandez-Santiago B, Beltran T, Schinazi RF. *Curr Top Med Chem.* 2004; 4:895–919. [PubMed: 15134548]
3. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. *AIDS.* 1998; 12:1735–1744. [PubMed: 9792373]
4. Chen CH, Cheng YC. *J Biol Chem.* 1989; 264:11934–11937. [PubMed: 2745424]
5. Shulman N, Winters M. *Curr Drug Targets Infect Disord.* 2003; 3:273–281. [PubMed: 14754429]
6. Lewis W, Day BJ, Copeland WC. *Nat Rev Drug Discov.* 2003; 2:812–822. [PubMed: 14526384]
7. Ohrui H, Kohgo S, Kitano K, Sakata S, Kodama E, Yoshimura K, Matsuoka M, Shigeta S, Mitsuya H. *J Med Chem.* 2000; 43:4516–4525. [PubMed: 11087576]
8. Watanabe KA, Reichman U, Hirota K, Lopez C, Fox JJ. *J Med Chem.* 1979; 22:21–24. [PubMed: 218006]
9. Hertel LW, Kroin JS, Misner JW, Tustin JM. *J Org Chem.* 1988; 53:2406–2409.
10. Marquez VE, Tseng CKH, Mitsuya H, Aoki S, Kelley JA, Ford H Jr, Driscoll JS. *J Med Chem.* 1990; 33:978–985. [PubMed: 2106581]
11. Pai SB, Liu SH, Zhu YL, Chu CK, Cheng YC. *Antimicrob Agents Chemother.* 1996; 40:380–386. [PubMed: 8834884]
12. Chun BK, Schinazi RF, Cheng YC, Chu CK. *Carbohydr Res.* 2000; 328:49–59. [PubMed: 11005575]
13. Klumpp K, Kalayanov G, Ma H, Pogam SL, Leveque V, Jiang WR, Inocencio N, Witte AD, Rajyaguru S, Tai E, Chanda S, Irwin MR, Sund C, Wingvist A, Maltseva T, Eriksson S, Usova E, Smith M, Alker A, Najera I, Cammack N, Martin JA, Johansson NG, Smith DB. *J Biol Chem.* 2008; 283:2167–2175. [PubMed: 18003608]
14. Schaefer OD, Verdine GL. *J Am Chem Soc.* 1995; 117:10781–10782.
15. Minakawa N, Takeda T, Sasaki T, Matasuda A, Ueda T. *J Med Chem.* 1991; 34:778–786. [PubMed: 1995901]
16. Siddiqui MA, Hughes SH, Boyer PL, Mitsuya H, Van QN, George C, Sarafinanos SG, Marquez VE. *J Med Chem.* 2004; 47:5041–5048. [PubMed: 15456247]
17. Graul A, Rabasseda X, Castaner J. *Drugs Future.* 1998; 23:133–141.
18. Maag H, Ryzewski RH, McRberts MJ, Crawford-Ruth D, Verheyden JPH, Priske EJ. *J Med Chem.* 1992; 35:1440–1451. [PubMed: 1573638]
19. Chang, J.; Bao, X.; Wang, Q.; Guo, X.; Wang, W.; Qi, X. Preparation of 2'-fluoro-4'-substituted nucleoside analogs as antiviral agents. Chinese Patent Application No: CN 2007-10137548. 20070807. Chinese Patent No: CN 101177442A, 20080514
20. Chang, J. 2'-Fluoro-4'-substituted nucleosides, the preparation and use. International Application No: PCT/CN2008/001239. 20080627. International Patent No: WO2009009951, 20090122
21. Chang, J. 2'-Fluorine-4'-substituted nucleoside analogues, preparation methods and uses thereof. US Patent. US 2010/0234584A1, 20100916.
22. Ma T, Pai SB, Zhu YL, Lin JS, Shanmuganathan K, Du J, Wang C, Kim H, Newton MG, Cheng YC, Chu CK. *J Med Chem.* 1996; 39:2835–2843. [PubMed: 8709113]
23. Jin YH, Bae M, Byun YJ, Kim JH, Chun MW. *Arch Pharm Res.* 1995; 18:364–365.
24. Smith DB, Kalayanov G, Sund C, Wingvist A, Maltseva T, Leveque VJP, Rajyaguru S, Pogam SL, Najera I, Benkestock K, Zhou XX, Kaiser AC, Maag H, Cammack N, Martin JA, Swallow S, Johansson NG, Klumpp K, Smith M. *J Med Chem.* 2009; 52:2971–2978. [PubMed: 19341305]
25. Pharmasset Inc. 2',4'-Substituted nucleosides as antiviral agents. International Patent. WO2009067409, 20090528. US Patent No: US 20090318380, 20091224
26. Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R, Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C, Pogam SL, Leveque V, Ma H, Maile G, Merrett JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N. *Bioorg Med Chem Lett.* 2007; 17:2570–2576.
27. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. *J Virol.* 1995; 69:6705–6711. [PubMed: 7474080]
28. Connor RI, Chen BK, Choe S, Landau NR. *Virology.* 1995; 206:935–944. [PubMed: 7531918]

29. Rong L, Bates P. *J Virol.* 1995; 69:4847–4853. [PubMed: 7609052]
30. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. *Cancer Res.* 1987; 47:943–946. [PubMed: 3802101]
31. Qian K, Yu D, Chen CH, Huang L, Morris-Natschke SL, Nitz TJ, Salzwedel K, Reddick M, Allaway GP, Lee KH. *J Med Chem.* 2009; 52:3248–3258. [PubMed: 19388685]
32. The solubility of compound **10** is 3.1 g in 100 g water. The solubility of compound **11** is 14.3 g in 100 g water.




Fig. 1. Structures of 1-(4'-Azido-2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)cytosine (**10**) and Its Design Lead 4'-Azido-thymidine.




Fig. 2.
X-ray Crystallographic Structure of Hydrochloride Salt **11**.





Fig 3.
Mechanism of Phosphorylated Compound 10.

**Scheme 1.**

Reagents and conditions: a) HBr/HOAc/DCM; b) silylated uracil(5-fluorouracil)/CHCl₃; c) NH₃/MeOH; d) Ph₃P/I₂/DMF; e) NaOMe/THF; f) ICl/NaN₃/THF; g) BzCl/Pyr.DCM; h) mCPBA/mCBA/DCM; i) 1. triazole/POCl₃/pyridine/DCM, 2. NH₄OH, 3. NH₃/MeOH; j) HCl, MeOH, EtOAc.

Table 1Anti-HIV activity of **10** and **11** against wild-type HIV-1 virus.

Compound	EC ₅₀ (nM) (wild-type) ^a
10	0.3
11	0.13
EFV	1.2
AZT	47

^aEC₅₀ (nM) is the concentration that inhibits HIV by 50%. Results were averaged from at least two separate experiments.

Table 2Anti-HIV activity of **11** against NL4-3 (wild-type), NL4-3 (K101E), and RTMDR.

Compound 11	EC ₅₀ (nM) ^a
NL4-3	0.086
NL4-3.K101E	0.15
HIV-1RTMDR	0.11

^aEC₅₀ (nM) is the concentration that inhibits HIV by 50%. Results were averaged from at least two separate experiments.

Table 3Anti-HIV activity of compound **11** against NIH reagent program NRTI-resistant virus panel.

NRTI Resistant Virus Panel	EC ₅₀ (nM) ^a
7324-1 (M41L, D67N, K70R, T215F, K219E, T69N)	0.595
7324-4 (M41L, K70R, T215F, K219E)	0.735
10076-4 (M41L, T215Y, M184V)	>40,000 ^b
7295-1 (D67N, K70R, T215F, K219Q, M184V, T69N)	>40,000
4755-5 (M41L, D67N, L210W, T215Y, M184V, T69D, E44D, V118I)	>40,000
6463-13 (M41L, D67N, L210W, T215Y, M184V, V118I)	>40,000
7303-3 (M41L, D67N, L210W, T215Y, T69D, E44D, V118I)	0.56
1617-1 (K70G, M184V, T69K, V75I, F77L, F116Y, Q151M)	32.2
35764-2 (V75I, F77L, F116Y, Q151M)	0.42
29129-2 (M41L, D67N, L210W, T215Y, M184V)	>40,000
56252-1 (K70R, V75I, F77L, F116Y, Q151M, K65R)	0.525
NL4-3 (wild-type)	0.318

^aEC₅₀ (nM) is the concentration that inhibits HIV by 50%. Results were averaged from at least two separate experiments.

^bThe highest concentration tested was 40,000 nM.

Table 4Cytotoxicity screening of compound **11** against six human cell lines.

Cells	IC ₅₀ (μM) ^a
TZM-BL (derived from HeLa Cells)	>140 ^b
HEPG-2	>140
293T	>140
MT4	0.12
ACH-2	0.11
PBMC (PHA activated)	0.15

^aIC₅₀ (μM) is the concentration that inhibits cell growth by 50%. Results were averaged from at least three separate experiments.

^bThe highest concentration tested was 140 μM.